Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Other Operating Expenses (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Other Operating Expenses data on record, last reported at $38.1 million in Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 147.66% year-over-year to $38.1 million; the TTM value through Dec 2025 reached $100.7 million, up 161.68%, while the annual FY2025 figure was $100.7 million, 161.69% up from the prior year.
  • Other Operating Expenses reached $38.1 million in Q4 2025 per TGTX's latest filing, up from $28.1 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $38.1 million in Q4 2025 and bottomed at $2000.0 in Q3 2022.
  • Average Other Operating Expenses over 5 years is $7.7 million, with a median of $2.7 million recorded in 2023.
  • Peak YoY movement for Other Operating Expenses: crashed 99.32% in 2022, then surged 175350.0% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $210000.0 in 2021, then crashed by 97.62% to $5000.0 in 2022, then soared by 156960.0% to $7.9 million in 2023, then soared by 96.12% to $15.4 million in 2024, then skyrocketed by 147.66% to $38.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $38.1 million in Q4 2025, $28.1 million in Q3 2025, and $18.9 million in Q2 2025.